CJC-1295 (no DAC) / Ipamorelin Blend – 5mg/5mg 
A Combined GHRH Analog and Selective GH Secretagogue Research Blend
A Dual-Pathway Growth-Hormone-Axis Research Blend for Somatotropic Studies

Category: Peptide Research Blends / Endocrinology / Growth Hormone Axis Biology

For Research Use Only. Not for human or veterinary use. Not a drug, supplement, or food additive. Intended exclusively for in-vitro and laboratory research by qualified investigators.

DISCLAIMER
ATTENTION: PRIMALRESEARCHLABS.COM products are intended for laboratory research and in-vitro studies only. All information presented is for educational and research purposes related to scientific investigation. These products are strictly not for human or veterinary use, consumption, or diagnostic applications. They are not pharmaceuticals, food additives, or dietary supplements. By purchasing from PRIMALRESEARCHLABS.COM, you acknowledge that you are a qualified researcher operating in a controlled laboratory environment. Adhere to all applicable local, state, and federal laws and regulations regarding handling and use of research chemicals. Use appropriate personal protective equipment (PPE) and follow laboratory safety protocols.

BIOLOGY
This blend combines two complementary growth-hormone-axis research peptides. CJC-1295 without DAC (also known as Mod GRF 1-29) is a synthetic analog of growth-hormone-releasing hormone (GHRH) that activates the GHRH receptor on pituitary somatotrophs. Ipamorelin is a selective pentapeptide growth-hormone secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a).

Because GHRH analogs and ghrelin-receptor agonists act through distinct but converging receptors on the same pituitary cells, the two peptides are studied together for potentially complementary stimulation of the somatotropic axis. Ipamorelin is notable for its receptor selectivity, releasing growth hormone with minimal effect on cortisol, prolactin, or ACTH. The combination makes a useful tool for in-vitro and in-vivo endocrinology research on growth-hormone regulation.

This product is intended solely for in-vitro and preclinical research use and is not for human or veterinary consumption.

Research note: This is a proprietary two-peptide blend. Supporting studies below characterize each component individually; controlled studies on this specific co-formulated combination are limited. Citations are provided at the component level.

KEY RESEARCH APPLICATIONS OF CJC-1295/IPAMORELIN

1. GHRH Receptor Activation (CJC-1295 no DAC)
The GHRH-analog component is studied for somatotropic signaling through:
• GHRH Receptor Binding: Activates pituitary GHRH receptors and cAMP signaling.
• GH Release: Stimulates growth-hormone synthesis and secretion.
• Preserved Pulsatility: Studied for maintenance of pulsatile GH secretion.
Supporting Studies:
Teichman, S.L. et al. — Journal of Clinical Endocrinology & Metabolism. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone.” PubMed – PMID: 16352683

2. Selective GH Secretagogue Activity (Ipamorelin)
The ghrelin-receptor agonist component is studied for selective GH release:
• GHS-R1a Agonism: Selective agonist at the ghrelin/GH-secretagogue receptor.
• Receptor Selectivity: Releases GH with minimal cortisol, prolactin, or ACTH effect.
• GH Pulse Stimulation: Produces discrete growth-hormone secretory episodes.
Supporting Studies:
Raun, K. et al. — European Journal of Endocrinology. “Ipamorelin, the first selective growth hormone secretagogue.” PubMed – PMID: 9849822

3. Somatotropic Axis & Synergy Research
Explored in growth-hormone-axis research through:
• Dual-Pathway Stimulation: Studied for combined GHRH + GHS receptor activation.
• IGF-1 Downstream Effects: GH stimulation studied for downstream IGF-1 elevation.
• Endocrine Modeling: Applied across pituitary and somatotropic research.
Supporting Studies:
Ionescu, M. & Frohman, L.A. — Journal of Clinical Endocrinology & Metabolism. “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295.” PubMed – PMID: 17018654

RECOMMENDED RESEARCH CONCENTRATIONS
For laboratory research reference only. Not for human or veterinary use.
• In-vitro pituitary cell assays — 1-100 nM (per component) — Assay buffer
• Receptor signaling studies — 1-50 nM — Cell culture media
• Animal models (rodents, SC) — Per protocol — Injection

WHY CHOOSE PRIMAL RESEARCH FOR YOUR CJC-1295/IPAMORELIN STUDIES?
• ≥98% HPLC-verified purity on both peptide components
• Independent third-party batch testing with COA available on request
• Lyophilized powder blend for maximum stability and long-term storage
• Pre-combined dual-pathway format supports GH-axis research protocols

STORAGE & HANDLING
• Store at -20°C, desiccated and protected from light
• Soluble in sterile water or bacteriostatic water
• Prepare fresh solutions prior to each experiment
• Avoid repeated freeze-thaw cycles

TECHNICAL SPECIFICATIONS
Compound: CJC-1295 (no DAC) / Ipamorelin Blend
Components: Mod GRF 1-29 (~3368 g/mol) + Ipamorelin (~712 g/mol)
Purity: ≥98% (HPLC Verified) per component
Form: Lyophilized powder — 5mg/5mg and 10mg/10mg blends
Storage: -20°C, desiccated, light-protected
Solubility: Soluble in sterile or bacteriostatic water
COA: Available per batch on request

ADVANCE YOUR RESEARCH
Order your CJC-1295 (no DAC) / Ipamorelin Blend today to support advanced research in growth-hormone-axis regulation, pituitary signaling, and somatotropic biology.

Primal Research products are sold strictly for in-vitro and laboratory research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease or condition. Purchasers are responsible for compliance with all applicable local, state, and federal regulations.